AIM
TEVA icon

Acropolis Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Acropolis Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,514
Closed -$101K – 135
2013
Q4 		$101K Sell
2,514
-769
-23% -$30.3K 0.02% 121
2013
Q3 		$124K Hold
3,283
– – 0.03% 120
2013
Q2 		$129K Buy
+3,283
New +$128K 0.03% 106

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Acropolis Investment Management's TEVA Position: Q1 2014 in Review

Acropolis Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2014, closing a stake of 2,514 shares — an estimated $101K sold.

Acropolis Investment Management first reported a position in TEVA in Q2 2013 and held it in 3 quarters. The position peaked at $129K in Q2 2013. 770 funds tracked by Wall St. Rank hold TEVA as of Q1 2014.

  • Acropolis Investment Management reported no remaining Teva Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Acropolis Investment Management sold 2,514 Teva Pharmaceuticals shares in Q1 2014, an estimated $101K.
  • Acropolis Investment Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Acropolis Investment Management's Teva Pharmaceuticals position peaked at $129K in Q2 2013.
  • 770 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2014.

Based on Acropolis Investment Management's 13F filing for Q1 2014, filed 30 Apr 2014.